The Hippo pathway transcription factors YAP and TAZ play HPV-type dependent roles in cervical cancer

被引:2
|
作者
Patterson, Molly R. [1 ,2 ]
Cogan, Joseph A. [1 ,2 ]
Cassidy, Rosa [1 ,2 ]
Theobald, Daisy A. [1 ,2 ]
Wang, Miao [1 ,2 ]
Scarth, James A. [3 ]
Anene, Chinedu A. [3 ,4 ]
Whitehouse, Adrian [1 ,2 ]
Morgan, Ethan L. [5 ]
Macdonald, Andrew [1 ,2 ]
机构
[1] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds LS2 9JT, England
[2] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds, England
[3] Queen Mary Univ London, Barts Canc Inst, London, England
[4] Leeds Beckett Univ, Ctr Biomed Sci Res, Leeds, England
[5] Univ Sussex, Sch Life Sci, Brighton, England
基金
英国医学研究理事会; 英国生物技术与生命科学研究理事会; 英国惠康基金;
关键词
EXPRESSION ANALYSIS; CELL-PROLIFERATION; ONCOPROTEINS; PHOSPHORYLATION; PACKAGE;
D O I
10.1038/s41467-024-49965-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Human papillomaviruses (HPVs) cause most cervical cancers and an increasing number of anogenital and oral carcinomas, with most cases caused by HPV16 or HPV18. HPV hijacks host signalling pathways to promote carcinogenesis. Understanding these interactions could permit identification of much-needed therapeutics for HPV-driven malignancies. The Hippo signalling pathway is important in HPV+ cancers, with the downstream effector YAP playing a pro-oncogenic role. In contrast, the significance of its paralogue TAZ remains largely uncharacterised in these cancers. We demonstrate that TAZ is dysregulated in a HPV-type dependent manner by a distinct mechanism to that of YAP and controls proliferation via alternative cellular targets. Analysis of cervical cancer cell lines and patient biopsies revealed that TAZ expression was only significantly increased in HPV18+ and HPV18-like cells and TAZ knockdown reduced proliferation, migration and invasion only in HPV18+ cells. RNA-sequencing of HPV18+ cervical cells revealed that YAP and TAZ have distinct targets, suggesting they promote carcinogenesis by different mechanisms. Thus, in HPV18+ cancers, YAP and TAZ play non-redundant roles. This analysis identified TOGARAM2 as a previously uncharacterised TAZ target and demonstrates its role as a key effector of TAZ-mediated proliferation, migration and invasion in HPV18+ cancers. The Hippo pathway transcription factors YAP and TAZ are often thought to play redundant roles in cancer progression. Here, Patterson et al demonstrate that TAZ is specifically required in HPV18+ cervical cancer, a subtype associated with worse prognosis.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Hippo-YAP/TAZ pathway regulation: the crucial roles of lncRNAs in cancer
    Jang, Wonyi
    Im, Mijung
    Roh, Jungwook
    Kang, Jihoon
    Kim, Wanyeon
    ANIMAL CELLS AND SYSTEMS, 2023, 27 (01) : 309 - 320
  • [2] The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin
    Rognoni, Emanuel
    Walko, Gernot
    CELLS, 2019, 8 (05)
  • [3] The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
    Cunningham, Richard
    Hansen, Carsten Gram
    CLINICAL SCIENCE, 2022, 136 (03) : 197 - 222
  • [4] Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment
    Buglioni, Simonetta
    Vici, Patrizia
    Sergi, Domenico
    Pizzuti, Laura
    Di Lauro, Luigi
    Antoniani, Barbara
    Sperati, Francesca
    Terrenato, Irene
    Carosi, Mariantonia
    Gamucci, Teresa
    Vincenzoni, Cristina
    Mariani, Luciano
    Vizza, Enrico
    Venuti, Aldo
    Sanguineti, Giuseppe
    Gadducci, Angiolo
    Barba, Maddalena
    Natoli, Clara
    Vitale, Ilio
    Mottolese, Marcella
    De Maria, Ruggero
    Maugeri-Sacca, Marcello
    ONCOIMMUNOLOGY, 2016, 5 (06):
  • [5] TARGETING THE YAP/TAZ HIPPO SIGNALING PATHWAY FOR ORAL CANCER TREATMENT
    Thiruvengadam, Muthu
    EXCLI JOURNAL, 2024, 23 : 1023 - 1026
  • [6] The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression
    He, Chunbo
    Mao, Dagan
    Hua, Guohua
    Lv, Xiangmin
    Chen, Xingcheng
    Angeletti, Peter C.
    Dong, Jixin
    Remmenga, Steven W.
    Rodabaugh, Kerry J.
    Zhou, Jin
    Lambert, Paul F.
    Yang, Peixin
    Davis, John S.
    Wang, Cheng
    EMBO MOLECULAR MEDICINE, 2015, 7 (11) : 1426 - 1449
  • [7] The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway
    Hong, Wanjin
    Guan, Kun-Liang
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2012, 23 (07) : 785 - 793
  • [8] SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway
    Zhang, Huixia
    Li, Shasha
    Zhou, Runxin
    Dong, Tianqi
    Zhang, Xiao
    Yu, Man
    Lin, Jiaming
    Shi, Mingjun
    Geng, Ershuo
    Li, Juebei
    Wang, Mingwei
    Huang, Liu
    Yang, Xiang -Ping
    Sun, Shuguo
    CANCER LETTERS, 2024, 585
  • [9] The Hippo-YAP/TAZ pathway mediates geranylgeranylation signaling in breast cancer progression
    Lin, Qiong
    Yang, Wannian
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (03)
  • [10] Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice
    Moya, Ivan M.
    Castaldo, Stephanie A.
    Van den Mooter, Laura
    Soheily, Soheil
    Sansores-Garcia, Leticia
    Jacobs, Jelle
    Mannaerts, Inge
    Xie, Jun
    Verboven, Elisabeth
    Hillen, Hanne
    Alguero-Nadal, Ana
    Karaman, Ruchan
    Van Haele, Matthias
    Kowalczyk, Weronika
    De Waegeneer, Maxime
    Verhulst, Stefaan
    Karras, Panagiotis
    van Huffel, Leen
    Zender, Lars
    Marine, Jean-Christophe
    Roskams, Tania
    Johnson, Randy
    Aerts, Stein
    van Grunsven, Leo A.
    Halder, Georg
    SCIENCE, 2019, 366 (6468) : 1029 - 1034